654 Results

People

  1. Motzer
    Motzer
  2. Mulhall
    Mulhall
  3. Saltz
    Saltz
  4. Hudis
    Hudis
  5. Abou-Alfa
    Abou-Alfa
  6. Lichtman
    Lichtman
  7. De Angelis
    De Angelis
  8. Ginsberg
    Ginsberg
  9. Russo
    Russo
  10. Feldman
    Feldman

Groups

  1. Department of Medicine (397)
  2. Solid Tumor Oncology Division (270)
  3. Hematologic Malignancies, Division of (99)
  4. Genitourinary Oncology Service (98)
  5. Survivorship Research (97)
  6. Surgery (84)
  7. Division of Subspecialty Medicine (78)
  8. Center for Hematologic Malignancies (77)
  9. Epidemiology and Biostatistics (69)
  10. Radiology, Department of (61)
  1. "hypertension"
Formats
  1. Journal Article (607)
  2. Review (31)
  3. Editorial (6)
  4. Guidelines (4)
  5. Research Letter (3)
  6. Book Section (1)
  7. Conference Paper (1)
  8. Correspondence (1)
Groups
  1. Department of Medicine (397)
  2. Solid Tumor Oncology Division (270)
  3. Hematologic Malignancies, Division of (99)
  4. Genitourinary Oncology Service (98)
  5. Survivorship Research (97)
  6. Surgery (84)

More Groups

People
  1. Robert Motzer (59)
  2. John Mulhall (21)
  3. Leonard Saltz (18)
  4. Clifford Hudis (16)
  5. Richard Steingart (14)
  6. Ghassan Abou-Alfa (13)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (31)
  4. 2022 (29)
  5. 2021 (23)
  6. 2020 (38)

More Years

Publications
  1. Journal of Clinical Oncology (41)
  2. Clinical Cancer Research (20)
  3. Lancet Oncology (20)
  4. Cancer (15)
  5. Journal of the National Comprehensive Cancer Network (15)
  6. Journal of Sexual Medicine (14)

More Publications

Publishers
  1. Elsevier Inc. (124)
  2. Elsevier Science, Inc. (58)
  3. Springer (47)
  4. American Society of Clinical Oncology (42)
  5. Oxford University Press (39)
  6. Wiley Blackwell (35)

More Publishers

Results (654)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • EZH2 inhibition by tazemetostat: Mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma
    Review

    Julia, E.; Salles, G.
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes
    Journal Article

    Mendoza, R. P.; Fyke, W.; Daniel, D.; Gabutan, E.; Das, B.; Bajaj, H.; Easy, M.; Vasileva, A.; Colbourn, R.; Alawad, M.; more...
    Human Immunology (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of atezolizumab plus bevacizumab following disease progression on atezolizumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma in IMmotion150: A randomized phase 2 clinical trial
    Journal Article

    Powles, T.; Atkins, M. B.; Escudier, B.; Motzer, R. J.; Rini, B. I.; Fong, L.; Joseph, R. W.; Pal, S. K.; Sznol, M.; Hainsworth, J.; more...
    European Urology (2021)

    Fulltext@MSK | Save
  • The importance of low-dose CT screening to identify emphysema in asymptomatic participants with and without a prior diagnosis of COPD
    Journal Article

    Steiger, D.; Siddiqi, M. F.; Yip, R.; Yankelevitz, D. F.; Henschke, C. I.; on behalf of the I-ELCAP investigators
    Clinical Imaging (2021)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma: New targets and novel therapies
    Review

    Cheson, B. D.; Nowakowski, G.; Salles, G.
    Blood Cancer Journal (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
    Journal Article

    Choueiri, T. K.; Powles, T.; Burotto, M.; Escudier, B.; Bourlon, M. T.; Zurawski, B.; Oyervides Juárez, V. M.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; more...
    New England Journal of Medicine (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study
    Journal Article

    Mato, A. R.; Shah, N. N.; Jurczak, W.; Cheah, C. Y.; Pagel, J. M.; Woyach, J. A.; Fakhri, B.; Eyre, T. A.; Lamanna, N.; Patel, M. R.; more...
    Lancet (2021)

    Fulltext@MSK | Save
  • Phase I study of the efficacy and safety of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant non-small cell lung cancer
    Journal Article

    Yu, H. A.; Paz-Ares, L. G.; Yang, J. C. H.; Lee, K. H.; Garrido, P.; Park, K.; Kim, J. H.; Lee, D. H.; Mao, H.; Wijayawardana, S. R.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes
    Journal Article

    Laccetti, A. L.; Garmezy, B.; Xiao, L.; Economides, M.; Venkatesan, A.; Gao, J.; Jonasch, E.; Corn, P.; Zurita-Saavedra, A.; Brown, L. C.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save